Compare LKQ & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKQ | HALO |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.8B |
| IPO Year | 2003 | 2001 |
| Metric | LKQ | HALO |
|---|---|---|
| Price | $31.37 | $68.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $42.33 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.35 | ★ 2.56 |
| Revenue | ★ $13,651,000,000.00 | $151,862,000.00 |
| Revenue This Year | $2.01 | $28.24 |
| Revenue Next Year | $1.64 | $12.79 |
| P/E Ratio | ★ $13.39 | $26.28 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.13 | $47.50 |
| 52 Week High | $44.30 | $82.22 |
| Indicator | LKQ | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 38.91 |
| Support Level | $29.30 | $67.94 |
| Resistance Level | $32.08 | $74.92 |
| Average True Range (ATR) | 1.13 | 2.36 |
| MACD | -0.29 | -0.67 |
| Stochastic Oscillator | 23.72 | 17.13 |
LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.